ES2539861T3 - Formulaciones en emulsión de clevidipina que contienen agentes antimicrobianos - Google Patents

Formulaciones en emulsión de clevidipina que contienen agentes antimicrobianos Download PDF

Info

Publication number
ES2539861T3
ES2539861T3 ES11833207.1T ES11833207T ES2539861T3 ES 2539861 T3 ES2539861 T3 ES 2539861T3 ES 11833207 T ES11833207 T ES 11833207T ES 2539861 T3 ES2539861 T3 ES 2539861T3
Authority
ES
Spain
Prior art keywords
clevidipin
antimicrobial agents
formulations containing
amount
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11833207.1T
Other languages
English (en)
Other versions
ES2539861T5 (es
Inventor
Rajeshwar Motheram
Gregory Charles Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medicines Co
Original Assignee
Medicines Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45925617&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2539861(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medicines Co filed Critical Medicines Co
Publication of ES2539861T3 publication Critical patent/ES2539861T3/es
Application granted granted Critical
Publication of ES2539861T5 publication Critical patent/ES2539861T5/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una formulación farmacéutica que comprende (a) clevidipina, o una sal o un éster farmacéuticamente aceptables de la misma, presente en una cantidad de aproximadamente el 0,01 hasta aproximadamente el 1,0 % p/v, (b) un agente antimicrobiano, presente en una cantidad de aproximadamente el 0,001 hasta aproximadamente el 1,0 % p/v, (c) un lípido, presente en una cantidad de aproximadamente el 2 hasta aproximadamente el 30 % p/v, (d) un emulsionante, presente en una cantidad de aproximadamente el 0,2 hasta aproximadamente el 2,0 % p/v, (e) un modificador de la tonicidad, presente en una cantidad de aproximadamente el 2 hasta aproximadamente el 3 % p/v, y (f) agua hasta el 100 %; en la que el agente antimicrobiano es EDTA.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10

Claims (1)

  1. imagen1
    imagen2
ES11833207.1T 2010-10-12 2011-10-10 Formulaciones en emulsión de clevidipina que contienen agentes antimicrobianos Active ES2539861T5 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39229410P 2010-10-12 2010-10-12
US392294P 2010-10-12
PCT/US2011/055617 WO2012051116A1 (en) 2010-10-12 2011-10-10 Clevidipine emulsion formulations containing antimicrobial agents

Publications (2)

Publication Number Publication Date
ES2539861T3 true ES2539861T3 (es) 2015-07-06
ES2539861T5 ES2539861T5 (es) 2018-11-16

Family

ID=45925617

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11833207.1T Active ES2539861T5 (es) 2010-10-12 2011-10-10 Formulaciones en emulsión de clevidipina que contienen agentes antimicrobianos

Country Status (18)

Country Link
US (1) US10010537B2 (es)
EP (1) EP2627173B2 (es)
JP (3) JP6040437B2 (es)
KR (2) KR101786857B1 (es)
CN (1) CN103237446B (es)
AU (1) AU2011313852B2 (es)
BR (1) BR112013008601B1 (es)
CA (1) CA2814495C (es)
DK (1) DK2627173T4 (es)
EA (1) EA022849B1 (es)
ES (1) ES2539861T5 (es)
HK (1) HK1187495A1 (es)
HU (1) HUE026295T2 (es)
MX (2) MX356537B (es)
NZ (1) NZ610465A (es)
PL (1) PL2627173T5 (es)
PT (1) PT2627173E (es)
WO (1) WO2012051116A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102170786B (zh) 2008-08-01 2015-05-27 医药公司 药物组合物和产生低杂质浓度的药物组合物的方法
US8658676B2 (en) * 2010-10-12 2014-02-25 The Medicines Company Clevidipine emulsion formulations containing antimicrobial agents
HUE026295T2 (en) 2010-10-12 2016-06-28 The Medicines Co Clevidipine emulsion formulations containing antimicrobial agents
BR112013025368A8 (pt) * 2011-04-01 2018-06-12 The Medicines Co Medicamento, método para preparar um medicamento útil para reduzir danos por derrame em um sujeito com derrame, método para preparar um medicamento útil para reduzir a pressão sanguínea e reduzir danos por derrame em um sujeito com derrame
EA030354B1 (ru) * 2012-10-26 2018-07-31 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Способ уменьшения диспноэ у пациента с острой сердечной недостаточностью
CN103169672A (zh) * 2012-12-26 2013-06-26 辰欣药业股份有限公司 一种丁酸氯维地平冻干乳剂
CN103110580B (zh) * 2013-02-20 2014-09-17 北京德立福瑞医药科技有限公司 丁酸氯维地平注射剂
CN103126986A (zh) * 2013-03-19 2013-06-05 董慧芳 一种丁酸氯维地平静脉注射用乳剂及其制备方法
TW201538181A (zh) * 2014-03-19 2015-10-16 Pures Biotech Co Ltd 用於潤滑保濕消毒滅菌之半流體組成物及其使用方法
WO2015179334A1 (en) * 2014-05-19 2015-11-26 The Medicines Company Clevidipine nanoparticles and pharmaceutical compositions thereof
CN105456189A (zh) * 2014-09-12 2016-04-06 武汉大安制药有限公司 一种丁酸氯维地平乳剂注射剂及其制备方法
CN104523590B (zh) * 2014-12-09 2017-09-15 山东威高药业股份有限公司 一种丁酸氯维地平脂肪乳注射液
CN107661294B (zh) * 2016-07-27 2020-04-14 武汉科福新药有限责任公司 抗高血压药物脂肪乳注射剂及其制备方法
WO2019123221A1 (en) * 2017-12-20 2019-06-27 Aurobindo Pharma Limited Pharmaceutical composition comprising clevidipine and process for preparation thereof
CN111671725B (zh) * 2018-01-26 2023-03-21 中国医学科学院阜外医院 用于保护缺血心肌的注射剂及其制备方法
CN109602704A (zh) * 2019-01-23 2019-04-12 广东嘉博制药有限公司 丁酸氯维地平脂肪乳注射液及其制备工艺
CN109776405A (zh) * 2019-03-07 2019-05-21 重庆安格龙翔医药科技有限公司 一种丁酸氯维地平杂质的制备方法
US11135208B2 (en) * 2019-08-12 2021-10-05 American Regent, Inc. 1,4-dihydropyridine compositions, methods of making and use

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4217842A1 (de) 1992-05-29 1993-12-02 Dietl Hans Calciumantagonisten enthaltende pharmazeutische Zubereitung zur intravenösen und intrakoronaren Applikation sowie Verfahren zu ihrer Herstellung
JPH08506081A (ja) 1993-02-12 1996-07-02 ファーモス コーポレイション サブミクロン・エマルジョンの調製のための乾燥組成物
SE9303657D0 (sv) 1993-11-05 1993-11-05 Astra Ab Short-acting dihydropyridines
SE9303744D0 (sv) 1993-11-12 1993-11-12 Astra Ab Pharmaceutical emulsion
GB9405593D0 (en) 1994-03-22 1994-05-11 Zeneca Ltd Pharmaceutical compositions
IT1275532B (it) 1995-07-14 1997-08-07 Recordati Chem Pharm Uso di derivati 1,4-diidropiridinici per la prevenzione e la terapia della degenerazione aterosclerotica della parete arteriosa
WO1998005334A1 (en) 1996-08-07 1998-02-12 Kyowa Hakko Kogyo Co., Ltd. Fat emulsion containing xanthine derivative
CA2319810C (en) 1998-02-10 2008-12-23 Gensia Sicor Inc. Propofol composition containing sulfite
IT1301807B1 (it) 1998-06-25 2000-07-07 Tiberio Bruzzese Formulazioni farmaceutiche iniettabili di derivati della partricina.
ATE285795T1 (de) * 1998-07-14 2005-01-15 Alcon Mfg Ltd Polypropylenbasierte behälter für prostaglandin- enthaltende produkte
SE9804002D0 (sv) 1998-11-23 1998-11-23 Astra Ab New manufacturing process
GB0012597D0 (en) 2000-05-25 2000-07-12 Astrazeneca Ab Formulation
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
EP1539122B1 (en) 2002-07-29 2014-01-29 Transform Pharmaceuticals, Inc. Aqueous 2,6-diisopropylphenol pharmaceutical compositions
US20060094699A1 (en) 2003-04-11 2006-05-04 Kampen Gita Camilla T Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
US20050186230A1 (en) * 2004-01-23 2005-08-25 Sd Pharmaceuticals, Inc. Elemene compositions containing liquid oil
ES2523147T3 (es) 2004-02-26 2014-11-21 Baylor Research Institute Composiciones y métodos para el tratamiento sistémico de la artritis
US20050271710A1 (en) 2004-06-04 2005-12-08 Argo Brian P Antimicrobial tissue products with reduced skin irritation potential
US20050282895A1 (en) 2004-06-21 2005-12-22 Dosch Michael H Antimicrobial compositions and methods of use thereof
US20100210506A1 (en) 2005-10-20 2010-08-19 Mdrna, Inc. Intranasal administration of rapid acting insulin
FR2900052B1 (fr) 2006-04-19 2011-02-18 Galderma Sa Composition comprenant au moins une phase aqueuse et au moins une phase grasse comprenant de l'ivermectine
JP5571380B2 (ja) 2006-07-24 2014-08-13 ルミナス バイオサイエンシズ，インコーポレイテッド オストワルド熟成を減少させた水不溶性の医薬品物質の固体ナノ粒子処方物
US20080206170A1 (en) 2006-12-07 2008-08-28 Belinda Tsao Nivaggioli Creatine compositions for skin treatment
US8303974B2 (en) 2007-06-11 2012-11-06 Edge Therapeutics, Inc. Drug delivery system for the prevention of cerebral vasospasm
EP2008651A1 (en) 2007-06-26 2008-12-31 Drug Delivery Solutions Limited A bioerodible patch
KR20160095206A (ko) 2008-08-01 2016-08-10 더 메디슨스 컴퍼니 약제학적 조성물 및 이를 안정화시키는 방법
CN102170786B (zh) 2008-08-01 2015-05-27 医药公司 药物组合物和产生低杂质浓度的药物组合物的方法
WO2010022259A1 (en) * 2008-08-22 2010-02-25 Milestone Pharmaceuticals Inc. Short acting benzothiazepine calcium channel blockers and uses thereof
US20100130619A1 (en) 2008-11-24 2010-05-27 Joseph Schwarz Pharmaceutical composition for parenteral administration of idebenone
CN101766668B (zh) 2008-12-30 2011-11-23 上海中医药大学 牛蒡子提取物及其制备方法和用途
CN101766568A (zh) 2008-12-31 2010-07-07 北京利乐生制药科技有限公司 一种含有氯维地平的乳剂及其制备工艺和用途
DE102009003980A1 (de) 2009-01-07 2010-07-08 B. Braun Melsungen Ag Propofol in triheptanoinhaltiger Trägeremulsion
CN101791311A (zh) 2009-12-31 2010-08-04 广州中大创新药物研究与开发中心有限公司 一种具有短效降压作用的药物组合物
CN101780036B (zh) 2010-03-30 2011-11-16 武汉武药科技有限公司 丁酸氯维地平脂微球注射液及其制备方法
HUE026295T2 (en) 2010-10-12 2016-06-28 The Medicines Co Clevidipine emulsion formulations containing antimicrobial agents

Also Published As

Publication number Publication date
CN103237446B (zh) 2014-11-05
CA2814495A1 (en) 2012-04-19
BR112013008601A2 (pt) 2017-07-25
JP6040437B2 (ja) 2016-12-07
BR112013008601B1 (pt) 2020-03-31
AU2011313852A8 (en) 2013-07-25
EP2627173B1 (en) 2015-03-25
KR20130101080A (ko) 2013-09-12
WO2012051116A8 (en) 2013-05-02
US10010537B2 (en) 2018-07-03
JP6437743B2 (ja) 2018-12-12
EP2627173A1 (en) 2013-08-21
CN103237446A (zh) 2013-08-07
CA2814495C (en) 2018-07-31
HK1187495A1 (en) 2014-04-11
AU2011313852A1 (en) 2013-05-09
MX2013004151A (es) 2013-05-20
JP2014504259A (ja) 2014-02-20
ES2539861T5 (es) 2018-11-16
EP2627173A4 (en) 2014-05-07
JP2014196322A (ja) 2014-10-16
PT2627173E (pt) 2015-07-24
AU2011313852B2 (en) 2015-07-02
BR112013008601A8 (pt) 2017-12-12
JP6326094B2 (ja) 2018-05-16
WO2012051116A1 (en) 2012-04-19
KR20160032266A (ko) 2016-03-23
EA201390541A1 (ru) 2013-11-29
MX356537B (es) 2018-06-01
KR101786857B1 (ko) 2017-10-18
DK2627173T3 (en) 2015-07-06
DK2627173T4 (en) 2018-10-22
HUE026295T2 (en) 2016-06-28
PL2627173T5 (pl) 2019-11-29
EP2627173B2 (en) 2018-07-04
US20120088804A1 (en) 2012-04-12
JP2016183183A (ja) 2016-10-20
EA022849B1 (ru) 2016-03-31
NZ610465A (en) 2015-05-29
PL2627173T3 (pl) 2015-08-31

Similar Documents

Publication Publication Date Title
ES2539861T3 (es) Formulaciones en emulsión de clevidipina que contienen agentes antimicrobianos
ES2524320T3 (es) Composición para la prevención o el tratamiento de enfermedad asociada con trombo o émbolo
ES2606342T3 (es) Composiciones para el cuidado bucal de sal estannosa y tripoli-fosfato de sodio y métodos
ES2494442T3 (es) Composiciones adyuvantes que comprenden un agente de isotonicidad no iónico
ES2487496T3 (es) Agente para aliviar el síndrome metabólico
ES2531646T3 (es) Composiciones de emulsión farmacéuticas con bajo contenido de aceite que comprenden progestágeno
CL2019000209A1 (es) Formulación novedosa administrable por la vía oral.
ES2546847T3 (es) Formulaciones de un inhibidor de la Src/Abl
CL2017000829A1 (es) Formulación farmacéutica que comprende mezcla de anticuerpo anti-alfa4beta7, un agente tamponante, y citrato; uso de dicha formulación para tratar enfermedad inflamatoria del intestino.
BR112014031837A2 (pt) formulações de progesterona
JP2015520235A5 (es)
ES2532948T3 (es) Composición tópica para el tratamiento de queratosis actínica
CL2011001225A1 (es) Formulacion farmaceutica en solucion acuosa que comprende desde 1% hasta 5% (p/v) de una sal de diclofenaco, desde 3% hasta 30% (p/v) de al menos un polioxialquilen ester de hidroxido de acido graso y un co-solvente seleccionado de etanol, propanol, glicerol, propilenglicol entre otros.
AR074391A1 (es) Composicion farmaceutica de un potente inhibidor de hcv para su administracion oral
PE20090910A1 (es) Composicion topica
ES2624577T3 (es) Formulación líquida que comprende un agonista de los receptores alfa-2 (por ejemplo, clonidina) y oxibutinina (agente antimuscarínico) para el tratamiento de sialorrea
CL2013003163A1 (es) Composición transdermica de ibuprofeno, util en el tratamiento del dolor o la inflamacion.
CL2019001366A1 (es) Formulaciones tamponadas exendina (9-39).
CY1108700T1 (el) Συνθεσεις απελευθερωσης φαρμακου εστερα αλφα-υδροξυ οξεος και μεθοδοι χρησης
CL2012003654A1 (es) Formulación farmaceutica estable para administracion intratecal que comprende una proteina arilsulfatasa a (asa), sal y un tensoactivo de polisorbato y/o un agente amortiguador, y que ademas puede contener un agente estabilizante; contenedor que comprende dicha formulacion; uso para tratar la enfermedad leucodistrofia metacromática (mld).
ES2478264T3 (es) Glicerosomas y uso de estos en preparaciones farmacéuticas y cosméticas para aplicación tópica
CL2011001621A1 (es) Composicion farmaceutica oral de liberacion sostenida que comprende en una forma de dosificacion unitaria, una matriz hidrofilica, un opioide, una sal de un aine, y opcionalmente un surfactante aniónico; y uso para preparar medicamentos utiles en la prevencion, alivio o disminución del nivel del dolor y supresión de la tos.
ECSP066670A (es) Prodroga florfenicol con mejor solubilidad en agua
PE20070377A1 (es) Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol
PE20110642A1 (es) Formulaciones antifungicas topicas a base de terbinafina y compuestos similares a terbinafina y metodos de uso